Corbion/€CRBN
1D1W1MYTD1Y5YMAX
Capital at risk
About Corbion
Corbion NV, trading under the ticker CRBN, is a Netherlands-based company specializing in biochemical ingredients. Operating within the biochemical sector, Corbion offers an extensive range of products including lactic acid and its derivatives, as well as other bio-based chemicals for various industries. Founded in 1919, the company has grown to serve a global market, providing ingredients and solutions for food, biochemical applications, and more.
- Ticker
- €CRBN
- Sector
- Materials
- Primary listing
- AEX
- Employees
- 2,363
- Headquarters
- Amsterdam, Netherlands
- Website
- www.corbion.com
Corbion Metrics
BasicAdvanced
€1.3B
21.39
€1.06
0.93
€1.00
2.82%
Price and volume
Market cap
€1.3B
Beta
0.93
52-week high
€22.70
52-week low
€16.20
Average daily volume
123K
Dividend rate
€1.00
Financial strength
Current ratio
1.834
Quick ratio
0.897
Long term debt to equity
0.478
Total debt to equity
0.685
Dividend payout ratio (TTM)
92.60%
Interest coverage (TTM)
8.56%
Profitability
EBITDA (TTM)
169.7
Gross margin (TTM)
25.05%
Net profit margin (TTM)
4.96%
Operating margin (TTM)
8.00%
Effective tax rate (TTM)
22.54%
Revenue per employee (TTM)
€530,000
Management effectiveness
Return on assets (TTM)
4.26%
Return on equity (TTM)
8.39%
Valuation
Price to earnings (TTM)
21.392
Price to revenue (TTM)
1.045
Price to book
1.73
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
17.318
Free cash flow yield (TTM)
5.77%
Free cash flow per share (TTM)
1.31
Dividend yield (TTM)
4.41%
Forward dividend yield
2.82%
Growth
Revenue change (TTM)
-3.37%
Earnings per share change (TTM)
-5.35%
3-year revenue growth (CAGR)
-3.91%
10-year revenue growth (CAGR)
3.12%
3-year earnings per share growth (CAGR)
-1.50%
10-year earnings per share growth (CAGR)
-4.86%
3-year dividend per share growth (CAGR)
4.55%
10-year dividend per share growth (CAGR)
4.06%
What the Analysts think about Corbion
Analyst ratings (Buy, Hold, Sell) for Corbion stock.
Analyst projections of the future price of Corbion stock.
Bulls say / Bears say
Q2 2026 showed a strong rebound, with organic sales growth of 8.5% and volume/mix growth of 10.7%, supporting Corbion’s maintained full-year organic-sales-growth outlook of 3–6%. (Corbion)
Biomaterials delivered a second consecutive record quarter, with growth across orthopedics, drug delivery and aesthetics; the planned divestment of the TotalEnergies Corbion joint venture was also progressing, potentially sharpening the portfolio. (Corbion)
Shareholders approved a €1.00-per-share dividend for 2025, comprising a €0.64 regular dividend and a €0.36 special dividend, providing tangible shareholder returns while the company executes its growth plan. (Corbion)
H1 2026 Adjusted EBITDA fell 16.7% year over year to €88.8 million, while the margin declined to 14.1% from 16.5%, indicating substantial earnings pressure despite positive organic sales growth. (Corbion)
Corbion reduced its full-year 2026 EBITDA-margin outlook to above 16% from approximately 17%, suggesting that mix effects, pricing and operational leverage remain more challenging than previously expected. (Corbion)
Cash conversion is a near-term risk: free cash flow was negative €4.0 million in H1 2026, while Q1 sales declined organically by 4.1% and Adjusted EBITDA fell organically by 19.7%; management also cited a weak North American food market. (Corbion)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Corbion Financial Performance
Revenues and expenses
Corbion Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Corbion
AllEURGBPUSD
Fund name | Fund size | €CRBN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.09% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.09% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.